Anthem Biosciences shares the shares 46% since the mention in the midst of strong financial growth

The Intelligence Group: Shares of Anthem Biosciences have been won 46% since the mention on July 21, despite the market volatility. Almost 11% of this was a profit after the company had announced strong numbers from June Kwartaal on 13 August.

The company, which offers drug discovery and production services to pharmaceutical customers, has carried out capacity expansion for adapted synthesis. It is planning to add 155 kiloliters of capacity to bring the total to 425 kiloliters at the end of September 2025. For FY26 it expects a turnover of 20%.

The company added 54 kiloliters of capacity in the quarter of June and 76 kiloliter more on behalf of the end of 2025. It will also add 40 kiloliters in Neoanthem, its subsidiary, by 2025 end.

The two products from the company that were in the archiving phase received approval, which increases the commercial portfolio to 12 from 10. This is good for its sales growth.

In the quarter of June, the turnover of Anthem Biosciences increased from the activities of 59.5% on an annual basis to £ 540.2 crore, while net profit increased by 64.8% to £ 135.8 crore. The growth of sales was powered by commercialized molecules and larger quantity requirements of five or six customers.

Anthem said that this drastic growth might not take place in every quarter and that is why it led for an annual revenue growth of around 20%, based on the 10-year historical growth, which is around 22%.

The operational margin for depreciation and amortization (EBITDA -Marge) fell to 38.1% of 39.2% a year ago. This was largely due to a sharing -based compensation costs of approximately £ 4.4 crore during the quarter, which was not in the previous year. If adapted for this, the margin was steady on an annual basis. The backward integration on one of the most important molecules has been done and the company is no longer dependent on external supply sources. The benefits of this can be seen in the gross margin of the company for the coming quarters.

Furthermore, obesity and diabetes that check drug GLP-1 will check the patent in several markets next year and Anthem has already delivered monsters to its customers. It works on developing the medicine. This offers a potential growth option.